Search the webpage

Category: Glaucoma

Experimentica Ltd. offers a validated human trabecular meshwork cells for a variety of custom in vitro projects targeted at the trabecular meshwork.

SUMMARY

Species

Human

In vitro insult

TBD

Format

96-well plate

Read-outs

Custom, e.g. actin fiber length, focal adhesions

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Representative examples from primary human trabecular meshwork  cells

Effect of the rho kinase inhibitor netarsudil on actin fiber arrangement in primary human trabecular meshwork cells. Netarsudil (1.2 µM) results in a significant reduction of actin fiber length as assessed by labeling with fluorescently-labelled phalloidin (Actin GreenTM 488 ReadyProbesTM, Thermo Fisher).

Effect of the rho kinase inhibitor netarsudil on focal adhesions in primary human trabecular meshwork cells. Netarsudil (1.2 µM) results in a significant reduction in the number of focal adhesions, as quantified using anti-paxillin antibody (clone 5H11, EMD Millipore).

SELECTED PUBLICATIONS

REFERENCES

  • Lin, C.-W. W. et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther 34, 40–51 (2018).

LATEST NEWS

Advances in preclinical in vivo imaging: OCT-Angiography of the rat retina

News
OCT-Angiography (OCT-A) scan of the adult rat retina. Already routinely used in the clinical setting, this non-invasive imaging technique to ... Read More

Experimentica at Bio Partnering event in Shanghai 2019

News
Experimentica Ltd. participates at Bio Partnering APAC conference in Shanghai, China, on September 24-25, 2019 ... Read More

Visit our poster in 17th European Congress of Toxicologic Pathology

News
Experimentica's partner Aiforia Technologies Oy will present joint poster dedicated for illustration of the effectivity of Aflibercept, administered systemically and ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!